“Shotgun Biopsy Needle Market to Reach USD 580 Million

“Shotgun Biopsy Needle Market to Reach USD 580 Million | 5.2% CAGR Growth & Trends”

Posted 2026-04-14 13:05:13

Shotgun Biopsy Needle Market is experiencing steady growth, supported by increasing cancer prevalence, rising demand for minimally invasive diagnostic procedures, and continuous innovation in medical device technology. According to the latest market analysis, the market was valued at approximately USD 380 million in 2024 and is expected to grow from USD 405 million in 2025 to USD 580 million by 2032, registering a compound annual growth rate (CAGR) of 5.2% during the forecast period.

Access a Complimentary Sample Report https://www.24lifesciences.com/download-sample/10300/shotgun-biopsy-needle-market

Shotgun biopsy needles are critical tools within modern diagnostic workflows, enabling precise and efficient tissue sampling for histopathological examination. Their widespread adoption across hospitals, clinics, and specialized diagnostic centers highlights their importance in oncology, radiology, and surgical disciplines, reinforcing the market’s relevance within the broader healthcare and life sciences ecosystem.

Market Highlights: Key Segmentation and Growth Drivers

The Shotgun Biopsy Needle Market is segmented by type, application, end user, needle gauge, and distribution channel, reflecting its diverse clinical use cases and procurement pathways.

By Type: Semi-Automatic Leads Market Adoption

Semi-automatic shotgun biopsy needles represent the leading segment, favored for the enhanced control they offer physicians during biopsy procedures. This feature is particularly valuable in complex anatomical locations, where procedural accuracy and reduced tissue trauma are critical. Fully automatic shotgun biopsy needles, while offering speed and consistency, are more commonly adopted in high-volume diagnostic environments where procedural efficiency is prioritized.

By Application: Hospitals Remain the Primary Setting

Hospitals dominate the market due to the high volume of diagnostic procedures, access to advanced imaging technologies, and presence of specialized departments such as oncology and interventional radiology. Clinics are emerging as a strong growth segment, driven by the shift toward outpatient care and minimally invasive diagnostics. The “Others” category, including ambulatory surgical centers and specialized diagnostic laboratories, further contributes to market diversification.

By End User: Radiologists at the Forefront

Radiologists are the predominant end users, as image-guided biopsy procedures form the core application of shotgun biopsy needles. Their reliance on precision instruments for ultrasound-, CT-, and MRI-guided sampling underpins this segment’s leadership. Oncologists and surgeons also play significant roles, utilizing these needles for cancer diagnosis and intraoperative tissue confirmation.

By Needle Gauge: Small Gauge Needles Dominate

Small gauge needles, such as 16G and 18G, account for the largest market share due to their ability to balance specimen adequacy with patient comfort. These needles minimize tissue trauma while delivering sufficient sample quality for accurate pathological analysis. Large gauge needles are reserved for specific clinical indications requiring larger tissue volumes.

By Distribution Channel: Direct Sales Lead Procurement

Direct sales dominate the distribution landscape, supported by strong manufacturer relationships with hospitals and group purchasing organizations. Distributors remain essential for serving smaller clinics and geographically dispersed markets, while third-party e-commerce platforms are emerging as a convenient procurement option for smaller healthcare facilities.

Access the Full Report Here https://www.24lifesciences.com/shotgun-biopsy-needle-market-10300

Emerging Trends Shaping the Healthcare Market

The Shotgun Biopsy Needle Market is influenced by broader trends across healthcare and life sciences. The integration of advanced imaging technologies, precision medicine, and data-driven diagnostics is reshaping biopsy procedures. Improvements in needle design, safety mechanisms, and tissue yield optimization align with the industry’s focus on minimally invasive care and patient-centric outcomes. Additionally, sustainability considerations and regulatory harmonization are guiding product development and market expansion strategies.

Regional Analysis: Global Market Performance

North America

North America holds a significant share of the Shotgun Biopsy Needle Market, supported by advanced healthcare infrastructure, high diagnostic procedure volumes, and early adoption of innovative medical devices.

Europe

Europe demonstrates steady growth, driven by strong regulatory frameworks, increasing cancer screening initiatives, and widespread availability of interventional diagnostic services.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth over the forecast period, fueled by expanding healthcare infrastructure, rising cancer incidence, and increased investment in diagnostic capabilities across emerging economies.

Rest of the World

Markets in Latin America, the Middle East, and Africa are gradually expanding as access to advanced diagnostic tools improves and healthcare systems modernize.

Competitive Landscape: Consolidation and Innovation Drive Market Dynamics

The global Shotgun Biopsy Needle Market is characterized by a concentrated and oligopolistic competitive landscape, with the top five players accounting for a substantial share of global revenue in 2024. Leading companies such as Biomedical and M.D.L. have established strong market positions through comprehensive product portfolios, robust distribution networks, and sustained R&D investment.

Other notable players include Medax, Amecath, Zamar Biopsy, GTA Medical, Edges Medicare Pvt. Ltd., Mermaid Medical, weLLgo Medical Products GmbH, Argon Medical Devices, Boston Scientific Corporation, Medtronic plc, Cook Medical LLC, Becton, Dickinson and Company, and Hologic, Inc. Competition is driven by product quality, technological innovation in semi-automatic and fully automatic systems, regulatory compliance, and pricing strategies. Strategic partnerships, mergers and acquisitions, and the launch of advanced safety-enhanced products continue to shape competitive dynamics.

Access the Full Report Here https://www.24lifesciences.com/shotgun-biopsy-needle-market-10300

Future Scenario: Steady Expansion Through 2032

Looking ahead, the Shotgun Biopsy Needle Market is poised for sustained growth through 2032, supported by a 5.2% CAGR, rising diagnostic demand, and continuous innovation in biopsy technologies. As healthcare systems increasingly prioritize early and accurate diagnosis, shotgun biopsy needles will remain essential tools across the diagnostic and therapeutic continuum.

Explore our related reports

About 24lifesciences

Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market

International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)

Website: www.24lifesciences.com